Search results

You searched for:
Results: 152
1

Respiratory

Chiesi Farmaceutici is fully committed to the care and improvement of the quality of life of people suffering from respiratory diseases including asthma and COPD (Chronic Obstructive Pulmonary Disease). Asthma and COPD are characterised by a reduction in the respiratory flow although they are...
2

Neonatology

Normally, delivery takes place between the 37th and the 42nd week of gestation. By that time, the fetus is fully formed and developed enough to be able to adapt to extra-uterine life. However, in some cases delivery may occur before the 37th week of gestation. In that case, the neonate is...
3

Rare Diseases

Chiesi has been focused on the centrality of the patient for decades. In 2019, Chiesi created a unit specifically dedicated to the development and commercialization of products for rare diseases to further increase our focus on the patients. Patients have been at the center of what we do for...
4

Pharmacovigilance

Pharmacovigilance is defined by the World Health Organization (WHO) as: The science and activities related to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem. The main objectives of pharmacovigilance in accordance with the...
5

Contacts

ΑΤΤΕΝΤΙΟΝ: In order to report side effects please visit the PHARMACOVIGILANCE page
6

Disclosure

-
7

Term of use

-
8

Therapeutic area

-
9

Join Chiesi

In terms of staffing, Chiesi’s basic philosophy is centered on internal promotions. Nowadays, most of the company’s executive personnel, such as product managers, area manager, etc., come from the sales department, having started as medical representatives.   To achieve this, the...
10

Products portfolio

-
11

Cookies

This website uses cookies to improve your browsing experience. By continuing to browse the website, you are consenting to our use of cookies. If you need more information and/or do not consent to the use of cookies, please visit this page. The cookie is a small piece of information stored on a...
12

We act - Sustainability Manifesto

We live in a time of great change. The equilibrium of a planet exploited beyond its limits is continuously evolving. We ourselves have changed the way we live and view society. The most fragile and vulnerable pay the price: those who are often left behind in this rush to make progress.   At...
13

Media

-
14

Mission and Values

Our aim is to be recognised as a research-focused international Group, able to develop and commercialise innovative pharmaceutical solutions to improve the quality of human life. We wish to maintain a high quality entrepreneurial team characterised by self-confidence and a collaborative...
15

Annual and Sustainability Report

-
16

B Corp

Chiesi is the largest global pharmaceutical group to be awarded B Corp Certification, a recognition of high social and environmental standards. It is an achievement to be proud of, and yet one that feels natural: caring for others lies at the root of health science and has always been at the heart...
17

History

THE PIONEERING AGE      1935-1955   The company was founded in Parma in 1935 when Giacomo Chiesi, a chemist who dreamed of doing research, bought the Laboratorio Farmaceutico Parmense and embarked on his entrepreneurial adventure.   In the early forties the...
18

Respiratory

-
19

Neonatology

-
20

Rare diseases

-
21

Search results

-
22

Sitemap

-
23

Privacy

-
24

Credits

  This project was edited and produced by Dynamic Mind.
25

Research and development

Innovation is the driving force behind every technologically advanced industry, but for the pharmaceutical industry it plays a vital role since it concerns the health and quality of life of people. For Chiesi, Research and Development are a true human and technological asset...
26

Other medicinal products

-
27

Medical Devices

-
28

Live events & Webcasts

Welcome to Live & on Demand scientific events organized by Chiesi Hellas
29

New openings

-
30

Products

-
31

Materiovigilance

Μateriovigilance is the activity relating to the monitoring of the safety and the collection of adverse effects and any other medical devices related problem. Materiovigilance is the activity that contributes to the protection of patient health.   Related link: National Organization for...
32

Κατευθυντήριες οδηγίες Facebook

-
33

Our approach

Sustainability has always been a primary concern in the way Chiesi operates and has increasingly become a focus with a view to shared value. Today, it represents a crucial element of the strategic vision of the company, which is committed to:  
34

Sustainability

-
35

We ACT - Sustainability Manifesto

We live in a time of great change. The equilibrium of a planet exploited beyond its limits is continuously evolving. We ourselves have changed the way we live and view society. The most fragile and vulnerable pay the price: those who are often left behind in this rush to make progress.   At...
36

Products and patients

With the theme "Products and patients" we refer to two dimensions closely related to each other: the final result of the company's production processes, namely our products, and the people who benefit from it. Our product lines are an expression of our mission, to improve the quality of life of...
37

Processes

At Chiesi, processes cover all production operations and those which enable the business to continue running, including decision-making procedures and internal company practices impacting employees and the biosphere.   We are committed to generating the following beneficial effects by means...
38

Environment

The concept of health has a much broader meaning at Chiesi and also encompasses that of the planet. This is also because the health of the planet and that of its inhabitants are interdependent. We therefore aim to act as a force for good and reduce the negative impacts on the areas where we...
39

Sustainability of our supply chain

The United Nations Global Compact defines supply chain sustainability as "the management of environmental, social and economic impacts and promotion of good governance practices throughout the entire life cycle of goods and services". This definition underlines the importance of bringing the...
40

Corporate Citizenship

Being a good citizen is a commitment a company makes to taking economic, social, cultural and environmental responsibility for its activities in the communities where it operates. Just like any other citizen, it has rights and duties. Inspired by the United Nations SDGs, we have created our own...
41

Communities

Chiesi’s commitment also involves promoting the development of local communities where the company operates, with the aim of facilitating sustainable growth in the area.   Sustainability at Chiesi also means recognising the strong interdependence between a company and the...
42

Ethics and Transparency

Guaranteeing the highest ethical standards is a daily priority for Chiesi in every aspect of its business. This means doing business on the basis of the principles of legality, fairness, integrity, responsibility and transparency.   In this regard, also in compliance with the laws and...
43

Chiesi Foundation

Our commitment goes beyond the areas where we operate to improve the health and relieve the suffering of patients with respiratory and neonatal diseases in countries where the company does not commercialise its products and where access to quality healthcare is not always guaranteed. This is the...
44

Sustainability Report

45

Our people

Chiesi employs around 6,000 people worldwide. Every day, we try to ensure an inclusive, familiar, safe and stimulating working environment for our employees, aiming to benefit from and enhance the value of cultural, gender, generational and ethnic diversity, because Every one of us is different,...
46

European and International Agenda

In accordance with the principles of interdependence deriving from the B Corp movement, we aim to constantly involve stakeholders in our sector (political decisionmakers, patient associations, scientific societies etc.) in order to further develop the regulatory and political framework of the...
47

Catena Globale del Valore

-
48

Gold award goes to Chiesi Hellas at the first Pharmacy Market Excellence Awards 2017

The first “Pharmacy Market Excellence Awards” held at the conference “Hellas PHARM 2017”,  awarded the gold medal in the category “Corporate Social Responsibility” to the pharmaceutical company Chiesi Hellas, for the many years of its contribution in the...
49

Chiesi Hellas is the major sponsor at the public awareness campaign for asthma and COPD

Chiesi Hellas is the major sponsor at the public awareness campaign for asthma and COPD, organized by the Hellenic Thoracic Society entitled “Your lungs are for life”. More information can be found at the following link of HTS: http://www.hts.org.gr/news/newsid510/255
50

PRESS RELEASE - GOLD Report 2017: Chiesi Farmaceutici highlights relevant gaps

Chiesi Farmaceutici welcomes the recently published GOLD report but identifies three key elements in the treatment recommendations, which deserve thorough evaluation and further review: - Limited documentation - Deviation from the approved product indications - Discrepancy with recent opinion of...
51

25th Panhellenic Congress on Thoracic Diseases

Chiesi Hellas sponsors the 25th Panhellenic Congress on Thoracic Diseases, organized by the Hellenic Thoracic Society (HTS), held 23-26 June at the Athens Hilton hotel. The active participation of the company includes the Satellite Symposium with the subject: “The treatment of inflammation...
52

Two awards go to Chiesi Hellas at the HR Excellence Awards 2016

Chiesi Hellas received an important distinction at the HR Excellence Awards 2016 of the Hellenic Management Association (HMA) and was awarded the Gold Award in the category Training & Development and the Silver Award in the category Leadership & People Excellence. With the educational...
53

Scientific event for Pharmacists

A scientific event for pharmacists was organized by Chiesi Hellas at the Acropolis Museum, on Monday 11 April 2016. The event highlighted the important role played by the pharmacist both in the successful onset and completion of the treatment of patients. “Patient compliance with treatment is...
54

Award to Chiesi Hellas for its contribution to the 'Social Clinic'

An event was held on Monday 22 February 2016, marking the completion of 4 years of operation of the Social Clinic, in the Great Room of the National and Kapodistrian University of Athens.   The event included the review of the work of the Social Clinic, the Athens Medical Association and the...
55

80 YEARS OF CHIESI GROUP’S CONTRIBUTION TO HEALTH AND RESEARCH

On the occasion of the celebration of the 80th anniversary of the founding of the CHIESI Group, the pharmaceutical company CHIESI HELLAS SA organized an event at the Museum of Cycladic Art, within the context of the exhibition “IASIS: Health, Disease, Treatment from Homer to Galen” on...
56

Chiesi Group and Holostem: An important step in regenerative medicine

We are pleased to announce that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a favorable opinion on Holoclar, the first stem cell treatment approved in Europe. Holoclar is produced in Modena at the labs of Holostem Terapie Avanzate S.r.l, a...
57

Standards of care: strength for preterm infants and their families

On Wednesday 10 December 2014 the event of “ILITOMINON” was held at the “Old Parliament”. ILITOMINON is a non-profit association for the care of preterm infants, member of the European Foundation for the Care of Newborn Infants (EFCNI).  The purpose of the event was to...
58

Clinical research for bronchopulmonary dysplasia of preterm infants

The clinical study NEUROSIS is an international multicentre clinical study which assessed the impact of inhaled budesonide on bronchopulmonary dysplasia (BPD), a frequent cause of morbidity and mortality in preterm infants. Positive results of the clinical study NEUROSIS The clinical study...
59

Health Race at Pyrgos Elis

A Health Race - Race Walking event was held in the morning of Sunday 19 October 2014 at Pyrgos, Elis with the active participation of residents of all ages. The goal of the Pyrgos municipality was to raise the awareness of citizens on matters of health, particularly of the respiratory system, since...
60

Chiesi Hellas supports the competition SFEE Innovation Project 2.0

Chiesi Hellas believes it is its duty to support young people and new ideas in the health field, supporting the competition for entrepreneurship and innovation in the health sector, “SFEE Innovation Project 2.0” of the Hellenic Association of Pharmaceutical Companies in cooperation with...
61

Exhibition IASIS: Health, Disease, Treatment from Homer to Galen Museum of Cycladic Art

Supporting Health through Art and Ancient Greek History, Chiesi Hellas is to sponsor the exhibition “IASIS” of the Museum of Cycladic Art to be held from November 2014 to May 2015.   With its sponsorship Chiesi Hellas supports the exhibition and “adopts” two exhibits...
62

Chiesi Hellas award at the Diamonds of the Greek Economy 2014

The honorary award of “The Most Admired Enterprises” went to Chiesi Hellas at the event held on Thursday 22 May 2014 by Stat Bank on its excellent course in the Greek business industry. “Diamonds of the Greek Economy” was launched 11 years ago and is the annual meeting of...
63

Social Clinic

Major support was offered to the Social Clinic and many collaborating Social Pharmacies by the Pharmaceutical Company CHIESI with the donation of 18,260 pieces of expectorant - mucolytic formulations.   2,000 formulations were delivered for the needs of the Social Clinic and its branches,...
64

Chiesi Hellas contributes to the sanitary needs of camps

Chiesi Hellas, supporting the program of the Metropolis of Glyfada-Ellinikon-Voula-Vouliagmeni-Vari, once again sponsored the replenishment and renewal of the pharmaceutical and sanitary products for the first aid of its camps.
65

Chiesi Group announces the acquisition of Zymenex

On 26 August 2013 the Chiesi Group reached an agreement for the acquisition of the company Zymenex Holding A/S, a pharmaceutical biotechnology group that focuses on the research and development of innovative biological treatments, for rare and life-threatening genetic illnesses. Zymenex Holding A/S...
66

Chiesi Hellas - Classical Music Evening

On Sunday, 14 July 2013, Chiesi Hellas was present, as a sponsor, at the Classical Music Evening organized by the Panorama Association “Creation”, at the theater of the square of the Holy Church of Agioi Myroforoi at Panorama Pallini. As “Man does not live by bread alone”,...
67

Chiesi Hellas once again sends help to Africa

Once again we support the work of the Orthodox Foreign Mission, through the Parish of the Holy Church of Agia Kyriaki, Palaio Faliro, sending antimalarial and gastroprotective drugs to Africa (Congo). Faithful to our commitment to relieve human pain, we will continue to support every effort in...
68

Chiesi Hellas donation to Africa

Chiesi Hellas supported the efforts of the Parish of the Holy Church of Agia Kyriaki in Palaio Faliro which actively participates in the work of the Orthodox Foreign Mission in Africa (Congo), providing them with 468 packs of proprietary formulations for respiratory and rheumatic diseases. For all...
69

Chiesi Hellas is currently a marketing authorization holder of the drug FLUIMUCIL

Chiesi Hellas is currently a marketing authorization holder of the drug Fluimucil in Greece. Fluimucil is a product of the Italian company Zambon and is manufactured in Switzerland. It is an expectorant-mucolytic agent available in sachets containing granules for oral suspension. The active...
70

Chiesi international clinical study in the journal BMC Pulmonary Medicine

The clinical study team LIAISON is pleased to announce that the text entitled ''International cross-sectional and longitudinal assessment on Asthma Control in European adult patients - the LIAISON study protocol'' has been accepted for publication in the journal BMC Pulmonary...
71

PRESS RELEASE: One of the synthetic pharmaceutical chemistry laboratories of the Athens Department of Pharmacy is being modernized by Chiesi Hellas

Modern laboratory and technological equipment ensures an upgraded educational and research environment Tuesday 22 January 2013. A modern and well-equipped laboratory is now available to the research team of Associate Professor Antonios Koulouris, a faculty member of the laboratory of Synthetic...
72

Chiesi Hellas sponsors the art exhibition of Kostas Spyropoulos

We are pleased to invite you to the opening of the art exhibition of Kostas Spyropoulos on Thursday 17 January 2013 at 7:30 pm at PERITEXNON KARTERIS (5 Irodotou Street, Kolonaki). The exhibition is from Thursday 17 January to Saturday 9 February 2013 and the hours are from Tuesday to Friday...
73

Chiesi reaches a strategic agreement with KAMADA

Chiesi and Kamada have made a strategic agreement on the availability of inhaled alpha-1 antitrypsin (A1AT) in Europe, the countries of the former Soviet Union and Turkey. Italian pharmaceutical company Chiesi Farmaceutici SpA and Kamada, an Israeli pharmaceutical biotechnology company, have...
74

LATEST DATA IN THE MANAGEMENT OF HYPERTENSION - Athens Concert Hall, 24-11-2012

Chiesi Hellas organizes, under the auspices of the Hellenic Society for Hypertension and Cardiovascular Protection, a scientific briefing on the subject: “LATEST DATA IN THE MANAGEMENT OF HYPERTENSION” The scientific event will take place Saturday 24 November 2012 at the MC2 Hall (N....
75

33rd PANHELLENIC CARDIOLOGY CONVENTION, 1-3/11/12 ATHENS HILTON HOTE

Chiesi Hellas will have a strong presence with an exhibition stand at the 33rd Panhellenic Cardiology Convention, to be held at the Athens Hilton hotel from 1-3 November 2012.
76

Chiesi Hellas embellishes the environment

Chiesi Hellas employees offered a beautiful visual intervention on a side street of Attiki Odos, aiming at enhancing the external environment and contributing to the quality of life of the residents of the surrounding area and the passing drivers as well as to the working quality of the...
77

Respiration Day 2012 - Press Release

PRESS RELEASE RESPIRATION DAY 2012 PERSONALIZED MEDICAL TREATMENT: APPLICATION TO RESPIRATORY DISEASES One of the challenges of treating patients with asthma and chronic obstructive pulmonary disease (COPD), is the different way in which patients respond to existing available treatments. This...
78

3rd Panhellenic Sales Conference, 28 June 2012

The 3rd Panhellenic Sales Conference is the continuation of the two previous extremely successful events, attended by more than 1,000 senior and upper level management executives from the private as well as the public sector, and many entrepreneurs. The Sales Institute of Greece in collaboration...
79

Launch of FOSTER in Cyprus

FOSTER, the first extrafine fixed combination of beclomethasone/formoterol via pMDI device, is officially circulating in Cyprus from Tuesday 5 June 2012.
80

Chiesi collaborates with Medical Pharmaquality

The company Medical Pharmaquality, after its successful course in the Greek pharmaceutical market this year, in which it introduced 10 generic drugs, announces its collaboration with the Italian pharmaceutical company...
81

Today’s reality and tomorrow’s prospects for diabetes and metabolic Diseases, DULAC Hotel, 30/3 - 01/04/2012

For the second consecutive year Chiesi Hellas will have a strong presence in the 2nd Scientific Event of the Institute of Diabetes & Metabolic Diseases to be held in Ioannina from 30 March to 1 April 2012, participating with a satellite speech and exhibition stand.   We invite you to the...
82

myasthma.gr: The site for asthma patients in Greece

Event for the official presentation of the first website for asthma patients in Greece, www.myasthma.gr by the Hellenic Thoracic Society and the asthma team. Saturday 7 April 2012 Hotel Grande Bretagne Grand Ballroom, Athens Start time: 19:30 The event is sponsored by Chiesi Hellas
83

First prize goes to Chiesi Hellas at the Pharmaceutical Marketing Excellence awards for the best communication campaign in the broad prescription category for FOSTER

Chiesi Hellas won the first prize at the “Pharmaceutical Marketing Excellence” awards at the 8th Conference of the Hellenic Pharmaceutical Marketing Company, in the category of best communication campaign in the broad prescription category with the FOSTER® product.   For more...
84

20th Panhellenic Congress of Thoracic Diseases, Athens 24-27 November 2011, Hotel Athens Hilton

Chiesi Hellas is organizing a satellite symposium on Saturday 26 November 2011 (12:30-14:00) at the Hotel Athens Hilton (Hall Terpsichori A) with the topic:  “Targeting small airways in obstructive diseases”  Coordinator: Nikolaos Siafakas  Our company is also pleased...
85

16th Panhellenic Congress of Perinatal Medicine

21 October - 23 October 2011 Megaron Athens International Conference Centre We are pleased to invite you to the satellite speech organized by our company, on Saturday 22 October 2011, time: 17:00-18:00, with the topic: “Latest views on the effect of caffeine on very low weight...
86

32nd PANHELLENIC CARDIOLOGY CONVENTION, 20-22/10/11 MACEDONIA PALACE HOTEL

Chiesi Hellas will have a strong presence with an exhibition stand at the 32nd Panhellenic Cardiology Convention, to be held at the Macedonia Palace hotel from 20-22 October 2011.  
87

ERS Annual Congress, Amsterdam 2011

We will be pleased to have you attend the satellite symposium of our company, to take place Tuesday 27 September 2011 (time 17:15-19:15), during the ERS Annual Congress in Amsterdam, with the topic: “REACH TREAT BENEFIT – THE VALUE OF TARGETING SMALL AIRWAYS IN RESPIRATORY...
88

3rd Educational Seminar, INSTITUTE OF STUDY, RESEARCH & TRAINING ON DIABETES MELLITUS AND METABOLIC DISEASES

“Modern developments in the diagnosis and treatment of metabolic diseases and associated pathological conditions”  30 September – 2 October 2011  Hotel Valis Resort, Agria Volos We invite you to attend the satellite speech organized by our company on Friday 30...
89

Chiesi Hellas sponsors the website www.epnel.gr Association of Pulmonologists of Greece

Visit the website www.epnel.gr
90

Chiesi Hellas sponsors the website www.iatroi-chanion.gr - Association of Freelance Physicians of Chania

Visit the website: www.iatroi-chanion.gr
91

Chiesi within the context of the ATS 2011 organizes a speech entitled Targeting Small Airways towards Optimal Therapeutic Management of Respiratory Disease'

Chiesi within the context of the ATS 2011 organizes a speech entitled "Targeting Small Airways towards Optimal Therapeutic Management of Respiratory Disease'' Speakers: Prof. Dirkje Postma and Prof. Peter Barnes Monday 16 May 2011 , 12:00 - 12:45 at the ATS conference center
92

2nd International Congress of Hypertension & Cardiovascular Protection, 27-30/1/11, DIVANI CARAVEL HOTEL

Open invitation to all health scientists. We are pleased to invite you to the satellite speech organized by our company, on Saturday 29 January, time 10:00-10:30 with the topic: “The position of calcium antagonists in the management of hypertension and cardiovascular risk. Latest data. The...
93

19th PANHELLENIC CONGRESS OF THORACIC DISEASES, 21-24/10/10, RODOS PALACE HOTEL- Open invitation to health scientists.

We invite you to the satellite speech organized by our company on Saturday 23 October, time 14:00-14:30 with the topic “Chiesi Hellas sponsors the online information of pulmonologists”. An updated self-assessment module will be presented on the website of the Hellenic Thoracic...
94

Chiesi Group receives the European Marketing Authorisation for Trimbow® (ICS/LABA/LAMA)

Parma, Italy 2017 – Chiesi Group (Chiesi), an international research-focused healthcare company, today announced that the European Commission has granted the marketing authorisation for Trimbow® for the treatment of Chronic Obstructive Pulmonary Disease (COPD) in adult patients. As a...
95

GIVMED | Pharma for the society: Chiesi Hellas shares medicine

The improvement of human health can be achieved in many ways, medical research is important, so is innovation but also social contribution. In the quest of these means GIVMED met the pharmaceutical company Chiesi Hellas and together they managed in a simple and reliable way to bridge a bit more the...
96

New study published in The Lancet shows Chiesi’s triple extrafine formulation superiority over indacaterol/glycopyrronium bromide

New study published in The Lancet shows fixed triple extrafine formulation superiority over indacaterol/glycopyrronium bromide   The TRIBUTE study showed superiority of Chiesi’s triple extrafine formulation over indacaterol/glycopyrronium bromide in terms of moderate to...
97

Βαδίζοντας σε νέες λύσεις με επίκεντρο τον ασθενή

-
98

Δρώντας στο παρόν, ατενίζοντας το μέλλον

-
99

Τριλογία νέων δεδομένων στη νέα εποχή διαχείρισης της ΧΑΠ

-
100

Βαδίζοντας σε νέες λύσεις, με επίκεντρο τον ασθενή

-
101

Ανασκόπηση ERS 2018

-
102

We Act Day

-
103

The evolution of inhalation therapies in asthma and COPD

-
104

ΕΡΩΤΑΠΑΝΤΗΣΕΙΣ ΣΤΗΝ ΠΝΕΥΜΟΝΟΛΟΓΙΑ 2019

-
105

--

-
106

--

-
107

--

-
108

Νέες προκλήσεις στο άσθμα και στη ΧΑΠ

-
109

--

-
110

Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic

PRESS RELEASE    Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic   The Group commits €3 million for donations to support the ongoing emergency in Italy Sustained efforts...
111

Η ΧΑΠ στην εποχή της COVID-19

-
112

COVID-19: Επιδημιολογία και διαχείριση ασθενούς

-
113

Chiesi Hellas – Μαζί και την επόμενη μέρα!

-
114

Chiesi Hellas supports the battle against COVID-19

  Chiesi Hellas supports in various ways the battle against COVID-19 in response to the critical condition that our country faces during the pandemic. Chiesi Hellas through the group health insurance program offers full coverage of the costs that an employee may incur if he is treated for...
115

Ανασκόπηση EAACI 2020

-
116

Global Head of R&D

Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group   Parma,  July 2, 2020 – Thomas Eichholtz is the new Head of Global Research and Development at the Chiesi Group. A senior leader with over 25 years’ experience in Research and...
117

--

-
118

Προσφορά σε τέσσερις «πράξεις» με το πρόγραμμα «We Act Day» από τη Chiesi Hellas

Δράσεις για το Περιβάλλον και την Κοινωνία σε...
119

Νεότερες Θεραπείες στη ΧΑΠ. Η ελληνική εμπειρία

-
120

Kaia Health and Chiesi Group Announce Strategic Partnership

Kaia Health and Chiesi Group Announce Strategic Partnership to Commercialise Kaia COPD Pulmonary Rehabilitation App in European Markets  Agreement marks a historic partnership for respiratory care in Europe     MUNICH and PARMA, November 30, 2020 -- Kaia Health, a leading...
121

Διαχείριση των αποφρακτικών παθήσεων. Προκλήσεις της καθημερινής ζωής

-
122

Εστιάζοντας στον ασθενή με αποφρακτικό νόσημα του πνεύμονα και συννοσηρότητες. Συζήτηση περιστατικών

-
123

Bέλτιστη διαχείριση του ασθενούς με αναπνευστικά συμπτώματα και συννοσηρότητες στην κλινική πράξη

-
124

Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support

  Company sponsors #wewearstripes social media campaign calling on participants to share photos to express support for people affected by rare diseases Company to light up offices around the world including Italy, the United States, and Canada   BOSTON, Mass. - February 26, 2021 -...
125

ΧΑΠ: Από την Παθοφυσιολογία στην θεραπεία

-
126

Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences

Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences   New visual identity is the first public manifestation of Chiesi Group’s continued transformation as a B Corp certified business Patients’ experiences and...
127

Rare Diseases Day 2021

#WeWearStripes     Ημέρα Σπάνιων Παθήσεων 2021 - #WeWearStripes εκστρατείας για τους...
128

Chiesi: Η Εμπειρία χτίζεται Μαζί

-
129

Πνευμονική αποκατάσταση στη ΧΑΠ

-
130

Περιοδικό Pharma & Health Business : Αφιέρωμα Εταιρική Κοινωνική Ευθύνη – H Chiesi Hellas ως δύναμη αειφορίας

-
131

Εστιάζοντας στον ασθενή με άσθμα

-
132

Αντιμετωπίζοντας την Covid-19: κλινική εμπειρία

-
133

Live symposium

-
134

Διάκριση της Chiesi Hellas στο θεσμό #BravoAwards

-
135

H CHIESI HELLAS ΕΛΑΒΕ ΤΙΜΗΤΙΚΗ ΔΙΑΚΡΙΣΗ ΣΤΗ ΦΕΤΙΝΗ ΔΙΟΡΓΑΝΩΣΗ PRIX GALIEN AWARDS, ΓΙΑ ΤΗ ΣΥΝΕΙΣΦΟΡΑ ΤΗΣ ΣΤΗΝ ΚΟΙΝΩΝΙΑ ΚΑΙ ΤΟ ΠΕΡΙΒΑΛΛΟΝ

H Chiesi δεσμεύεται να εξασφαλίσει ουδέτερο ισοζύγιο...
136

Προσωποποιημένη φροντίδα ασθενών με Άσθμα

Με χαρά σας προσκαλούμε να παρακολουθήσετε...
137

FOSTER® pMDI 100mcg/6mcg per actuation

Pharmaceutical form: Pressurised inhalation solution INN: Beclometasone dipropionate and Formoterol fumarate dihydrate
138

Peyona® 20 mg/ml

Pharmaceutical form: Solution for infusion and Oral solution INN: Caffeine citrate
139

Curosurf® 120 mg/ 1,5 ml & 240 mg/ 3 ml

Pharmaceutical form: Endotracheopulmonary instillation, suspension INN: Poractant alfa (Pig Lung Surfactant)
140

Budiair® 200 mcg per actuation

Pharmaceutical form: Pressurised inhalation solution INN:  Budesonide
141

Forair® 12mcg per actuation

Pharmaceutical form: Pressurised inhalation solution INN:  Formoterol fumarate dihydrate
142

Manyper® 10mg/tab, 20mg/tab

Pharmaceutical form: Tablets INN: Manidipine dihydrochloride
143

VIVACE® (30+10)mg/tab

Pharmaceutical form: Tablets INN: Delapril hydrochloride & Manidipine dihydrochloride
144

Bramitob® 300 mg/ 4 ml

Pharmaceutical form: Nebuliser solution INN: Tobramycin
145

Trimbow® 87/5/9 μg pressurised inhalation solution

Pharmaceutical form: pressurised inhalation solution INN: Each delivered dose (the dose leaving the mouthpiece) contains 87 micrograms of beclometasone dipropionate, 5 micrograms of formoterol fumarate dihydrate and 9 micrograms of glycopyrronium (as 11 micrograms...
146

THERA°PEARL® Sports Pack

THERA°PEARL® Hot / Cold Pack Multi-zones   Suitable for all parts of the body. Practical for direct use. Does not leak or stain.   Delivers soothing relief from: Muscle pain – Contracture Rupture Cut – Hematoma Arthritis For more information: ...
147

THERA°PEARL® Ankle / Wrist Wrap

THERA°PEARL® Hot / Cold Pack Ankle / Wrist Wrap with Strap Multi-zones   Conforms perfectly to the ankle or wrist, not to restrain you from your everyday job. Is doctor-designed for perfect adaptation. THERA°PEARL® technology allows it to be wrapped around the area of...
148

THERA°PEARL® Back Wrap

THERA°PEARL® Hot / Cold Pack Back Wrap with Strap   Back pain is one of the most frequent pains. The specially designed THERA°PEARL® is comfortable with adjustable strap to keep it firmly into its place.   Delivers soothing relief from: Lower or upper back...
149

THERA°PEARL® Knee Wrap

THERA°PEARL® Hot / Cold Pack Knee Wrap with Strap   The special design of the product by doctors, allows movement, while TheraPearl technology provides relief where needed. The strong strap with Velcro keep product in position even during exercise.   Delivers soothing relief...
150

TheraPearl Pals® for Kids

THERA°PEARL® Hot / Cold Pack For Kids   THERA°PEARL® Pals animals will help you coping with children's accidents.   Delivers soothing relief from: Minor boo-boos Cut/Bruise/Bump Headache Insect bites   For more information:  www.therapearl.gr
151

Becloneb® 400 mcg/1ml vial, 800 mcg/2ml vial

Becloneb® 400 mcg/1ml vial, 800 mcg/2ml vial Pharmaceutical form: Nebuliser suspension INN: Βeclometasone dipropionate
152

Beclospin® 400 mcg/1ml vial, 800 mcg/2ml vial

Beclospin® 400 mcg/1ml vial, 800 mcg/2ml vial Pharmaceutical form: Nebuliser suspension INN: Βeclometasone dipropionate
?>